# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ida B. Wells (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET022-SYN
- Date: 2026-01-05
- Fictional facility: St. Posthumous Health Center
- Fictional author: Cordelia Ashworth-Banks, MD
- Calendar frame: modern shifted

## What we are working on

- She wants to know exactly how sick her kidneys are, how the number was calculated, and why an earlier result was called normal **S**
- She wants to keep working and finish her memoir **S**

## Your goals

- Blood pressure below 130/80 mmHg in the clinic and at home within two months of starting treatment, and lower if tolerated. Target: 2026-03-03. Recorded outcome: 132/80 in the clinic and 130/78 at home on losartan 50 mg and dapagliflozin; losartan increased to 100 mg. **S**
- Urine albumin-to-creatinine ratio lower by at least 30% at the three-month check on treatment. Target: 2026-03-03. Recorded outcome: 240 and 228 mg/g at baseline; repeat due at three months on treatment. **S**
- No NSAIDs or other avoidable kidney harms; every medicine checked against her kidney function. Target: 2026-03-03. Recorded outcome: Naproxen stopped at intake; acetaminophen used instead; medicines checked at every visit. **S**
- An informed decision about APOL1 genetic testing, made by her after counseling. Target: 2026-01-20. Recorded outcome: Counseled at the consultation; she chose to defer the test and may ask for it at any time. **S**
- She understands her stage, her risk and the kidney replacement options, and her wishes are recorded, long before any decision is needed. Target: 2026-02-17. Recorded outcome: Kidney education session completed; wishes recorded at the annual wellness visit. **S**

## What we agreed to do

- Nephrology consultation for reduced kidney function (race-free eGFR 38) with albuminuria of uncertain cause, a 5-year kidney failure risk above 5% if the disease proves chronic, and APOL1 genetic counseling. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026) **S**
- Confirm and stage the kidney disease: race-free eGFR from creatinine with cystatin C, repeat urine albumin-to-creatinine ratio, urinalysis with microscopy, kidney ultrasound, a monoclonal protein screen (serum protein electrophoresis and free light chains), hepatitis B, hepatitis C and HIV tests, and any earlier results she can obtain. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease (2021); New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race (2021) **S**
- Blood pressure: a validated home monitor with readings twice a day for seven days to confirm the diagnosis; sodium below 2 g a day; recheck in two weeks. Guideline: KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026) **S**
- Stop over-the-counter naproxen and use acetaminophen for knee aching; avoid all NSAIDs; tell every clinician and pharmacist about her kidneys before new medicines or contrast dye. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026) **S**
- Anemia and mineral and bone checks: hemoglobin with iron studies, calcium, phosphate, intact PTH and 25-hydroxyvitamin D at baseline. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update (2017); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026) **S**
- Baseline ECG, TSH for tiredness, a lipid panel once at diagnosis, A1c to screen for diabetes, and a PHQ-9. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023) **S**
- On the nephrologist's advice: losartan 50 mg daily with potassium and creatinine in two weeks, then dapagliflozin 10 mg daily with a further check at two to four weeks, then losartan increased to the highest dose tolerated; sick-day rules for both; atorvastatin 20 mg; vitamin D3 1,000 units daily with PTH and vitamin D again at three months; blood pressure goal below 130/80 and a systolic below 120 if tolerated. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update (2017); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026) **S**
- APOL1 genetic testing offered after counseling on what a result would and would not change, on privacy, and on what it could mean for relatives; her decision to defer recorded, with the offer left open. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024) **S**
- Kidney education session on the kidneys and the treatment options if they fail (transplant, home and center dialysis, and conservative kidney management), long before any decision is needed; kidney diet session with the dietitian. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026) **S**
- Vaccines for chronic kidney disease: high-dose influenza, PCV20 and two doses of HepB-CpG (she was not immune), then RSV, recombinant zoster and COVID-19, spaced at her request. Guideline: Adult Immunization Schedule by Age (2026) **S**
- Dapagliflozin 10 mg daily started now that potassium and creatinine are stable on losartan. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026) **S**
- Losartan increased to 100 mg; potassium and creatinine in two to four weeks; urine albumin-to-creatinine ratio, hemoglobin, PTH and vitamin D at three months on treatment; nephrology review at three months. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026) **S**

## Follow-up

- 2026-01-05: New patient visit for tiredness and ankle swelling, with kidney function, urine albumin, blood count, and mineral and bone tests **S**
- 2026-01-20: Two-week review of home blood pressure readings, the repeat urine test and the kidney ultrasound, with the nephrology consultation **S**
- 2026-02-03: Two weeks after starting losartan: potassium, creatinine and blood pressure, and the decision about dapagliflozin **S**
- 2026-02-17: Subsequent annual wellness visit **S**
- 2026-03-03: Four weeks after starting dapagliflozin: potassium, creatinine and blood pressure, the losartan dose, and the plan for the months ahead **S**

This teaching document does not replace care from a qualified clinician.
